In draft report, ICER says Amylyx's ALS drug would not be cost effective if priced similarly to older treatment
Roughly 24 hours after Canadian regulators gave Amylyx Pharmaceuticals the thumbs-up for its new ALS drug, ICER is out with a new analysis trying to determine whether the drug would be cost effective. And the short answer is no — for now.
Though Amylyx has not disclosed how much it intends to charge for the drug, branded as Albrioza, ICER pegged its estimated cost to an older ALS medicine, edaravone. If Albrioza costs $169,000 per year, as edaravone currently does, the drug would not be cost effective to the US healthcare system, and far from it, ICER says.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.